Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Moodys
AstraZeneca
McKinsey
McKesson

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,129,343


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,129,343
Title:Acylated GLP-1 compounds
Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
Inventor(s): Lau; Jesper (Farum, DK), Bloch; Paw (Taastrup, DK), Hansen; Thomas Kruse (Herlev, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:11/908,834
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Recent additions to Drugs Protected by US Patent 8,129,343

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Novo OZEMPIC semaglutide SOLUTION 209637 Dec 5, 2017 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo OZEMPIC semaglutide SOLUTION 209637 Apr 9, 2019 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Novo RYBELSUS semaglutide TABLET 213051 Sep 20, 2019 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free U-2628 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
Novo WEGOVY semaglutide SOLUTION 215256 Jun 4, 2021 RX Yes ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,129,343

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-001 Dec 5, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS ⤷  Try it Free
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-002 Apr 9, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-001 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-002 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-003 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-004 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-005 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,129,343

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05102171Mar 18, 2005
PCT Information
PCT FiledMarch 20, 2006PCT Application Number:PCT/EP2006/060855
PCT Publication Date:September 21, 2006PCT Publication Number: WO2006/097537

International Family Members for US Patent 8,129,343

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 476446 ⤷  Try it Free
Australia 2006224536 ⤷  Try it Free
Brazil PI0607762 ⤷  Try it Free
Canada 2601784 ⤷  Try it Free
China 101133082 ⤷  Try it Free
China 104017062 ⤷  Try it Free
China 104402989 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
McKesson
Moodys
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.